In the last trading session, 1.22 million Solid Biosciences Inc (NASDAQ:SLDB) shares changed hands as the company’s beta touched 2.29. With the company’s per share price at $2.67 changed hands at -$0.27 or -9.18% during last session, the market valuation stood at $206.91M. SLDB’s last price was a discount, traded about -361.42% off its 52-week high of $12.32. The share price had its 52-week low at $2.77, which suggests the last value was -3.75% down since then. When we look at Solid Biosciences Inc’s average trading volume, we note the 10-day average is 1.27 million shares, with the 3-month average coming to 2.51 million.
Analysts gave the Solid Biosciences Inc (SLDB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SLDB as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Solid Biosciences Inc’s EPS for the current quarter is expected to be -0.54.
Solid Biosciences Inc (NASDAQ:SLDB) trade information
Instantly SLDB was in red as seen at the end of in last trading. With action -22.50%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -33.25%, with the 5-day performance at -22.50% in the red. However, in the 30-day time frame, Solid Biosciences Inc (NASDAQ:SLDB) is -47.54% down. Looking at the short shares, we see there were 7.84 million shares sold at short interest cover period of 1.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is 19, meaning bulls need an upside of 85.95% from its current market value. According to analyst projections, SLDB’s forecast low is 12 with 20 as the target high. To hit the forecast high, the stock’s price needs a -649.06% plunge from its current level, while the stock would need to soar -349.44% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 41.25%. The 2025 estimates are for Solid Biosciences Inc earnings to increase by 28.29%, but the outlook for the next 5-year period is at 18.18% per year.
SLDB Dividends
Solid Biosciences Inc is expected to release its next quarterly earnings report on 2025-Mar-05.
Solid Biosciences Inc (NASDAQ:SLDB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.70% of Solid Biosciences Inc shares while 62.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 62.68%. There are 62.24% institutions holding the Solid Biosciences Inc stock share, with PERCEPTIVE ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 16.8725% of the shares, roughly 6.91 million SLDB shares worth $39.16 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 10.579% or 4.33 million shares worth $24.55 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 3.51 shares estimated at $9.38 million under it, the former controlled 4.53% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.10% of the shares, roughly 854.68 shares worth around $2.28 million.
